trending Market Intelligence /marketintelligence/en/news-insights/trending/c5nbqkegk-h7gzhu2jtbxg2 content esgSubNav
In This List

Clearside Biomedical eye treatment succeeds in phase 3 study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Clearside Biomedical eye treatment succeeds in phase 3 study

Clearside BioMedical Inc. said its eye treatment CLS-TA significantly improved the vision of certain patients with macular edema in a late-stage study.

Macular edema occurs when damaged blood vessels cause a build-up of fluid in the retina, the light-sensitive part of the eye, resulting in distortion of vision.

The Alpharetta, Ga.-based biopharmaceutical company was studying the treatment in a phase 3 trial known as Peachtree, which enrolled 160 patients.

Of the 155 patients that completed the study, 47% of those that received the CLS-TA treatment had an improvement in their vision, compared to 16% of those that underwent a placebo procedure.

Clearside Biomedical will seek U.S. approval of the treatment in the fourth quarter. The company is also evaluating options for regulatory filings for the therapy elsewhere.

The company's stock was up 41.56% following the news to $11.20 per share as of 10:05 a.m. ET on March 5.